Brief: Antengene Announces IND Approval In China For A Global Phase III Trial Of Selinexor In Advanced Or Recurrent Endometrial Cancer
13/05/2021 01:42
May 12 (Reuters) - Antengene Corporation Ltd 6996.HK :
* ANTENGENE ANNOUNCES IND APPROVAL IN CHINA FOR A GLOBAL
PHASE III
TRIAL OF SELINEXOR IN ADVANCED OR RECURRENT ENDOMETRIAL CANCER
Source text for Eikon: ID:nPn92S6zTa
Further company coverage: 6996.HK
((Reuters.Briefs@thomsonreuters.com;))
Recent news on Antengene
See all newsBiotech firm Antengene's H1 revenue jumps on licensing deals
Brief: Antengene Corp Expects HY Profit Of RMB195 MLN-RMB238 MLN
Brief: Antengene Corp Receives Initial $60 Million Upfront Payment From UCB
Brief: Antengene Corp Intends To Repurchase Up To 67.92 Million Shares
Brief: Antengene Corp Enters Exclusive License Agreement With K2 Therapeutics For Atg-106